Genenta Science SPA
GNTA
View Detailed Chart
2.460USD
+0.160+6.96%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
47.10MMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.96%
5 Days
-18.27%
1 Month
-25.45%
6 Months
-41.05%
Year to Date
-43.45%
1 Year
-46.87%
View Detailed Chart
TradingKey Stock Score of Genenta Science SPA
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genenta Science SPA's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
21.000
Target Price
+543.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Genenta Science SPA Highlights
StrengthsRisks
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Overvalued
The company’s latest PE is -7.05, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.96M shares, decreasing 10.49% quarter-over-quarter.
Genenta Science SPA News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Genenta Science SPA Info
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Ticker SymbolGNTA
CompanyGenenta Science SPA
CEOMr. Pierluigi Paracchi
Websitehttps://www.genenta.com/
Related Instruments
+2.09%
-0.46%
+0.41%
-1.07%
+0.39%
+0.63%
+7.81%
+0.44%
-0.34%
+1.28%
-0.22%
-1.11%
+0.31%
+1.93%
-0.28%
-0.11%
0.00%
+2.58%
+2.62%
-3.19%Popular Symbols
